Reports Suggest Intentional 토토사이트추천 Cuts Amid Declining Prescription Volumes
Concerns are growing over the unstable 토토사이트추천 of Concerta OROS Extended-Release Tablets (active ingredient: methylphenidate) in South Korea. Reports indicate that the volume of outpatient prescriptions is gradually declining, fueling speculation that Janssen Korea is redirecting 토토사이트추천 to other markets amid concerns over potential price reductions.
Pharmaceutical distributors and medical institutions confirm that Concerta’s availability has become inconsistent. Industry sources suggest that ongoing concerns about price cuts and potential misuse have intensified these 토토사이트추천 issues.
In January and February 2025, Janssen Korea’s sales department indicated that shipment volumes would decrease compared to previous years. This was later confirmed as procurement figures matched these expectations. A pharmacy department representative from a major hospital in South Korea noted, “Even within medical institutions, it has become difficult to secure the necessary stock. Internal inquiries suggest 토토사이트추천 will not meet demand.”
Adding to the uncertainty, rumors have emerged that Janssen Korea has instructed sales teams to limit engagement with private clinics, further restricting access to the medication.
Industry analysts suspect Janssen Korea is deliberately reducing Concerta’s 토토사이트추천 due to a sharp decline in prescription volumes. According to UBIST, a pharmaceutical market research firm, outpatient prescription sales for Concerta’s four product lines fell from .7 million in 2022 to .8 million in 2023, then further to .6 million in 2024—a 15.3% decline in 2023 and a 13.9% drop in 2024. This is a stark contrast to the steady growth seen until 2022.
Experts emphasize that this decline exceeds the rate of price reductions for Concerta, which saw consecutive cuts of 5.0%–5.3% in 2023 and 2024. Given that generic alternatives have not significantly gained market share, analysts believe 토토사이트추천 reductions, rather than pricing alone, are driving the decrease.
A pharmaceutical distributor commented, “For a non-reimbursed drug, such a sharp year-over-year decline is unusual, particularly for a medication unrelated to infectious diseases or recent public health crises.”
Online discussions have further fueled speculation. Some patients claim doctors have attributed the shortage to government-imposed price reductions, prompting Janssen to redirect 토토사이트추천 to China. Distribution sources have echoed similar claims.
Regardless of speculation, industry observers are closely monitoring Concerta’s pricing and availability trends. Persistent price reductions have likely impacted profitability, raising the possibility that Janssen is prioritizing markets with higher pricing potential, such as China. With uncertainty surrounding future 토토사이트추천 strategies, further developments warrant close scrutiny.